companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

FOSECO CANADA INC

GUELPH-Canada

Company Name:
Corporate Name:
FOSECO CANADA INC
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 361 Speedvale Ave W,GUELPH,ON,Canada 
ZIP Code:
Postal Code:
N1H 
Telephone Number: 5196536429 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
0 
USA SIC Description:
 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
FOUNTAIN PEN THE
FOUNDATION FOR THE SUPPORT OF
FOSTET MANUFACTURING INC
Next company profile:
FOSECO CANADA INC
FOSECO MORVAL DIVISION OF FOSECO CANAD
FOSECO CANADA INC










Company News:
  • ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
    ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion
  • HIGHLIGHTS OF PRESCRIBING INFORMATION - enjaymo. com
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENJAYMO safely and effectively See full prescribing information for ENJAYMO ENJAYMO® (sutimlimab-jome) injection, for intravenous use Initial U S Approval: 2022
  • ENJAYMO® (sutimlimab-jome) | What is ENJAYMO?
    ENJAYMO is a chemotherapy-free treatment proven to help stop the destruction of red blood cells (hemolysis) in cold agglutinin disease (CAD)
  • ENJAYMO® (sutimlimab-jome) | How ENJAYMO Can Help Treat CAD
    ENJAYMO is a chemotherapy-free treatment option that helps stop hemolysis in its tracks What Happens in people living with CAD When you have Cold Agglutinin Disease (CAD), your immune system makes cold agglutinin antibodies that mistake red blood cells as a threat to the body When the antibodies come close to a red blood cell, they attach
  • ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing
    The ENJAYMO dosing schedule is designed to provide a continuous level of medicine ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter
  • ENJAYMO® (sutimlimab-jome) | Resources
    ENJAYMO resources and tools to help you get the information you need for people with cold agglutinin disease (CAD)
  • ENJAYMO® (sutimlimab-jome) | What is Cold Agglutinin Disease?
    ENJAYMO ® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) It is not known if ENJAYMO is safe and effective in children
  • ENJAYMO® (sutimlimab-jome) | Patient Solutions
    ENJAYMO Patient Solutions is here to help you with disease and treatment education as well as financial assistance for eligible patients
  • ENJAYMO® (sutimlimab-jome) | FAQ
    ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B
  • Prescriber, please complete page 2 and have patient read and sign page 3.
    information, with ENJAYMO the is medically information necessary on this form and any prescription to Recordati Rare Diseases, Inc (together with its parents and afiliates, “Recordati”) and its third-party business partners, I acknowledge vendors, that I and have other obtained agents authorization (“Agents”) to for release the




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer